Address: 20F Park Place, 1601 Nanjing West Road, Shanghai 200040,China
Tel: +86 21 2211 8888
Web: http://www.msdchina.com.cn/Pages/home.aspx
Merck Sharp and Dohme (MSD) is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, MSD discovers, develops, manufactures and markets vaccines and drugs to address unmet medical needs. MSD China was formed in 1994 in partnership with Hangzhou Huadong Medicine Group Co. Ltd. From the beginning, MSD China has been a socially responsible, innovative company contributing to improved health and economic growth.
With more than 2200 highly skilled, motivated employees throughout the country, MSD China is committed to bringing its high quality medicines and vaccines to the Chinese people. To date, the company has launched 4 new vaccines as well as 15 innovative drugs to treat cardiovascular diseases , serious infections, respiratory and musculoskeletal conditions, urinary problems and neurological disorders.Through MSD China’s research partnerships in China, it is possible to isolate and test the company’s best drug candidates against specific disease targets, and develop new biomarkers to contribute to the early detection and treatment of various forms of cancer.
MSD China expert chemical and manufacturing engineers produce numerous medicines for the Chinese market in a state-of-the-art, 12,000m2, production facility in Hangzhou. MSD China’s sales and marketing team is made of some of China’s top business talent from leading universities.
Human resources is one of MSD China’s greatest assets and its commitment to social causes is firmly anchored in its culture . In 1989, MSD transferred its innovative hepatitis B vaccine technology to China for $1 ; MSD built two high-tech manufacturing plants and trained Chinese scientists and engineers to produce the vaccine. As a result of this collaboration and the outstanding immunization programs led by China’s Centers for Disease Control, hepatitis b infection rates declined from 10 percent of the population in 1989 to less than 1 percent today. MSD is also proud to participate to the first large-scale public-private partnership for HIV/AIDS prevention and control in China. In collaboration with China’s Ministry of Health, the partnership provides access to HIV education, training, testing, counseling, treatment and care through more than 1600 implementing organizations. MSD has committed USD 30 million to support this partnership and is dedicated to improving the lives of HIV/AIDS patients and their families in China.
cardiovascular, infectious diseases, respiratory, musculoskeletal, neurology
MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps…
The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines…
George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management changes of the group, the value that PAREXEL…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, the cardiology treatment, Neucardin®. With…
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
Dr Yangzhou Wang, chief operations officer of Crown Bioscience (CrownBio), shares the new era of development for the company following its acquisition by a Japanese industrial conglomerate in December 2017;…
See our Cookie Privacy Policy Here
